We Make Drugs Work
We Make Drugs Work
We value nothing more important than life.
Through our AI technology, we strive to develop drugs for every single patient suffering from intractable disease.
Our Mission
Oncocross is innovating the drug development process through its unique AI approach.
We develop treatments for cancers, rare diseases, and intractable diseases through our transcriptome data based AI platform.
Technology
Oncocross AI platform identifies the optimal disease indications and drugs.
Business Value
Oncocross AI technology efficiently improves the drug development process.
-
Unrivaled Database Quality
We analyze transcriptome data of patients, drugs, and diseases.
-
Maximize the Value of a New Drug
We maximize the value of a new drug by identifying additional indications.
-
Fast Entry into Clinical Trials
We shorten the development time by identifying candidate drugs for any given disease.
-
High Success Rate of Clinical Trials
We identify the optimal indications by analyzing drug and disease expression data.
Medically Driven Database
Medically Curated Transcriptome Database
-
Patients
1
0
9
0
9
,
,
0
9
0
9
0
9
-
Drugs
2
2
5
4
,
,
0
9
0
9
0
9
-
Diseases
4
4
1
0
0
9
-
Cancer Types
4
3
0
9
Collaboration
We develop new drugs in collaboration with various pharmaceutical companies and research institutes.
-
RAPTOR AI™
New Indication
- Input
- Transcriptome data of cells before and after drug treatment, Transcriptome data of normal and diseased tissues
- Output
- New indication, Best partner drug
-
ONCO-RAPTOR AI™
Optimal Cancer Type Identification
- Input
- Transcriptome data of anti-cancer cells before and after drug treatment, Cancer types transcriptome data which includes prognosis information
- Output
- Optimal cancer types, Companion diagnostic biomarkers
-
ONCOfind AI™
CUP Primary Site Identification
- Input
- CUP patients’ cancer tissue transcriptome data
- Output
- CUP primary site identification, Optimal anti-cancer treatment
-
PIPELINE
Ongoing New Drug Projects
- In-house and partnered pipelines on oncology, rare diseases, intractable diseases, and metabolic diseases
Oncocross presents a new paradigm for
AI drug development
Join Oncocross’s innovation